CRMD
CorMedix Inc
7.90$
+1.0%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -10.2% | -17.1% | -15.1% | +34.4% | +53.2% | +25.9% | +68.9% | +197.3% | +10.0% | -1.3% | +10.8% | |
| – | -10.8% | -20.2% | -16.1% | +37.5% | +56.6% | +26.4% | +71.2% | +4.6% | +41.4% | +4.4% | +25.4% | |
| – | -18.1% | -19.4% | -18.9% | +23.6% | +15.2% | +63.1% | +140.3% | -69.6% | +200.7% | +22.1% | +44.1% | |
| – | -12.2% | -23.0% | -22.1% | +0.9% | +12.3% | +49.9% | +146.1% | -70.8% | +168.4% | +19.1% | +44.1% | |
| – | – | – | +20,633,600.0% | +8,326.7% | +197.1% | +5.7% | -21.4% | +273.0% | +7.0% | -9.6% | +4.2% | |
| – | – | +10.2% | +72.9% | +65.8% | +14.3% | -1.5% | +28.7% | +200.1% | +2.8% | +3.4% | +25.6% | |
| – | – | – | – | – | – | – | – | – | +71.3% | +0.0% | +0.0% | |
| – | – | – | -2.6% | -2.7% | -2.7% | -2.8% | -2.9% | +22,311.1% | -2.8% | -2.7% | -2.8% | |
| – | +44.9% | -16.0% | +15.3% | +63.5% | +81.1% | +1.5% | -7.9% | +1,078.4% | +11.7% | -10.0% | +17.1% | |
| – | +48.6% | -16.4% | +16.5% | +66.3% | +83.1% | +1.6% | -7.8% | +321.4% | +30.4% | -26.1% | +45.5% | |
| – | +2.8% | +2.8% | +2.8% | +2.7% | +2.7% | +2.7% | +2.7% | +703.5% | +1.8% | – | – | |
| – | +79.4% | -34.0% | +18.3% | -59.8% | +28.0% | +12.4% | +200.8% | +251.7% | -61.5% | +62.7% | -20.2% | |
| – | – | – | – | – | – | – | – | – | +0.1% | +0.2% | +0.2% | |
| – | -15.7% | -17.3% | -20.4% | +27.1% | +44.2% | +35.7% | +92.0% | +69.6% | +8.3% | +7.8% | +5.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1.5% | +0.2% | +0.2% | +2.1% | +4.6% | +12.1% | +4.3% | +19.9% | +8.9% | -1.0% | -0.5% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.